Richiedi una copia del documento: Clinical outcomes of metastatic renal carcinoma following disease progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). A Meet-URO group real world study (Meet-Uro 7)

Captcha code
Annulla